First slide
CytoCell fluorescence in situ hybridisation (FISH) logo.

Product summary

  • Technology FISH
  • Application Haematology
  • Areas of interest ALL, Lymphoma
  • Region 9p21.3
    9q12
  • Label    
  • Product Code LPH 009 (10 tests)
    LPH 009-S (5 tests)
  • Regulatory Status In vitro diagnostic. This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples. Disease information supported by the literature and is not a reflection of the intended purpose of this product.

Chromomaps

Overview

Probe specification

  • P16, 9p21.3, Red
  • D9Z3, 9q12, Green

The P16 probe, labelled in red, covers a 193kb region of 9p21.3, extending from 105kb telomeric of P16 gene to 46kb centromeric of CDKN2B. The probe mix also contains a control probe for chromosome 9 (D9Z3, the heterochromatic block at 9q12) labelled in green.

 

Probe information

The CDKN2A (cyclin-dependent kinase inhibitor 2A) gene at 9p21 is a tumour suppressor gene that has been shown to be deleted in wide range of human malignancies.

Loss of the CDKN2A gene results in cellular proliferation and dysregulation of pro-apoptotic pathways. There are two proteins produced by the CDKN2A gene: p16INK4a and p14ARF, these protein products have been linked to two tumour suppressor pathways: the RB pathway and the p53 pathway, respectively1.

Deletions of 9p that include the CDKN2A gene are frequently reported in patients with acute lymphoblastic leukaemia (ALL): in approximately 30% of adult B-cell ALLs, 30% of childhood ALLs and up to 50% of T- cell ALLs. In adult B-cell ALL, CDKN2A deletions are frequently acquired in disease progression2,3,4,5.

Deletions including the CDKN2A locus have been reported in up to a third of patients with diffuse large B-cell lymphoma (DLBCL)6 and, in glioma, CDKN2A loss has been implicated with shorter overall survival in WHO grade I-III astrocytomas7.

Losses of the CDKN2A region have also been reported in malignant mesothelioma, melanoma, and bladder cancer8,9,10.

What our customers say

References

  1. Møller MB, et al., Leukemia. 1999 Mar;13(3):453-9
  2. Moorman A V, et al., Blood. 2007;109(8):3189-97
  3. Sulong S, et al., Blood. 2014;113(1):100-7
  4. Schwab CJ, et al., Haematologica .2013 Jul;98(7):1081-8
  5. Xu N, et al., J Cancer. 2015;6(11):1114-20
  6. Jardin F, et al., Blood. 2010;116(7):1092-104
  7. Reis GF, et al., J Neuropathol Exp Neurol. 2015 May;74(5):442-52
  8. Conway C, et al., Genes Chromosomes Cancer. 2010 May;49(5):425-38
  9. Relan V, et al., PLoS One. 2013;8(3):e58132
  10. Stadler WM, et al., Clin Cancer Res. 2001;7(6):1676-82

Recommended protocol for CytoCell haematology FISH

Select a protocol step to view:

Sample and slide preparation

Icon representing the sample and slide preparation stage of the fluorescence in situ hybridisation (FISH) protocol.
  • Spot the cell sample onto a glass microscope slide. Allow to dry.
  • Immerse the slide in 2x Saline Sodium Citrate (SSC) for 2 minutes at room temperature (RT) without agitation.
  • Dehydrate in an ethanol series (70%, 85% and 100%), each for 2 minutes at RT.
  • Allow to dry.
Haematology FISH protocol Video Image
Play the video.

Haematology FISH protocol

Request a quote for this product

FISH resources & support